Mark Neumann - 01 Mar 2024 Form 4 Insider Report for Intra-Cellular Therapies, Inc. (ITCI)

Reporting relationship: EVP, Chief Commercial Officer
Issuer ticker: ITCI
Reported as of: 01 Mar 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Mar 2024, 19:05:00 UTC
Prior SEC filing: 27 Feb 2024
Next SEC filing: 08 Mar 2024
Source filing: View source filing
Reporting owner signature: /s/ Lawrence J. Hineline, Attorney-in-fact

Key filing fact

Mark Neumann filed Form 4 for Intra-Cellular Therapies, Inc. (ITCI) on 05 Mar 2024.

Key facts

This page summarizes Mark Neumann's Form 4 filing for Intra-Cellular Therapies, Inc. (ITCI).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 05 Mar 2024, 19:05.

Change

Previous filing in this sequence was filed on 27 Feb 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ITCI transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +26,227
Change %
Price: $0.000000
Shares after: 26,227
Date: 01 Mar 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 26,227
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of common stock.

Footnote F2

On March 1, 2024, the reporting person was granted 26,227 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.